Price is trading at a discount to the lowest analyst target ($3.70) and well below the mean ($4.86). While currently under the 50D/200D MAs ($3.60), the convergence suggests a pivot point. High beta (2.55) requires a wider stop below recent support ($3.33) to absorb volatility. This is a speculative play on analyst consensus despite negative EBITDA.